A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Phase 2/3 Completed 48 enrolled Avid Radiopharmaceuticals Eli Lilly and Company · collab

Non-randomizedSingle-groupOpen-labelDiagnostic

Summary

Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).

Timeline

Start: 2012-10
Primary completion: 2013-02
Completion: 2013-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	florbetapir F 18	Diagnostic / imaging agent	370 mbq	Intravenous

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Summary

Timeline

Drugs

Indications